125 related articles for article (PubMed ID: 16354323)
1. New approaches to treatment for multiple myeloma: durable remission and quality of life as primary goals.
Durie BG
Clin Lymphoma Myeloma; 2005 Nov; 6(3):181-90. PubMed ID: 16354323
[TBL] [Abstract][Full Text] [Related]
2. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma. A report of the French Registry on Autologous Transplantation in Multiple Myeloma.
Harousseau JL; Attal M; Divine M; Marit G; Leblond V; Stoppa AM; Bourhis JH; Caillot D; Boasson M; Abgrall JF
Stem Cells; 1995 Aug; 13 Suppl 2():132-9. PubMed ID: 8520502
[TBL] [Abstract][Full Text] [Related]
3. Role of new treatment approaches in defining treatment goals in multiple myeloma--the ultimate goal is extended survival.
Durie BG
Cancer Treat Rev; 2010 May; 36 Suppl 2():S18-23. PubMed ID: 20472184
[TBL] [Abstract][Full Text] [Related]
4. Stem-cell transplantation for multiple myeloma in the era of novel drugs.
Bensinger W
J Clin Oncol; 2008 Jan; 26(3):480-92. PubMed ID: 18056678
[TBL] [Abstract][Full Text] [Related]
5. New questions about transplantation in multiple myeloma.
Hari P; Pasquini MC; Vesole DH
Oncology (Williston Park); 2006 Sep; 20(10):1230-42; discussion 1242, 1244, 1249-50. PubMed ID: 17024872
[TBL] [Abstract][Full Text] [Related]
6. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
[TBL] [Abstract][Full Text] [Related]
7. Emerging trends in the clinical use of bortezomib in multiple myeloma.
Richardson PG; Schlossman R; Mitsiades C; Hideshima T; Munshi N; Anderson K
Clin Lymphoma Myeloma; 2005 Sep; 6(2):84-8. PubMed ID: 16231845
[TBL] [Abstract][Full Text] [Related]
8. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélome.
Roussel M; Lauwers-Cances V; Robillard N; Hulin C; Leleu X; Benboubker L; Marit G; Moreau P; Pegourie B; Caillot D; Fruchart C; Stoppa AM; Gentil C; Wuilleme S; Huynh A; Hebraud B; Corre J; Chretien ML; Facon T; Avet-Loiseau H; Attal M
J Clin Oncol; 2014 Sep; 32(25):2712-7. PubMed ID: 25024076
[TBL] [Abstract][Full Text] [Related]
9. Evolving role of stem cell transplantation in multiple myeloma.
Harousseau JL; Moreau P
Clin Lymphoma Myeloma; 2005 Sep; 6(2):89-95. PubMed ID: 16231846
[TBL] [Abstract][Full Text] [Related]
10. Integrating novel therapies in the transplant paradigm.
Harousseau JL
Cancer J; 2009; 15(6):479-84. PubMed ID: 20010167
[TBL] [Abstract][Full Text] [Related]
11. Induction therapy before transplantation in multiple myeloma: new strategies to achieve complete response.
Wu KL; Sonneveld P
Clin Lymphoma Myeloma; 2005 Sep; 6(2):96-101. PubMed ID: 16231847
[TBL] [Abstract][Full Text] [Related]
12. Role of thalidomide in the treatment of patients with multiple myeloma.
Morgan GJ; Davies FE
Crit Rev Oncol Hematol; 2013 Oct; 88 Suppl 1():S14-22. PubMed ID: 23827438
[TBL] [Abstract][Full Text] [Related]
13. High complete remission rate and durable remissions achieved with rational use of autologous stem-cell transplantation, thalidomide maintenance, and non-myeloablative allogeneic transplantation in patients with multiple myeloma.
Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
Clin Transplant; 2009; 23(6):839-47. PubMed ID: 20447186
[TBL] [Abstract][Full Text] [Related]
14. Treatment of multiple myeloma.
San Miguel JF; Bladé Creixenti J; García-Sanz R
Haematologica; 1999 Jan; 84(1):36-58. PubMed ID: 10091392
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib plus dexamethasone followed by escalating donor lymphocyte infusions for patients with multiple myeloma relapsing or progressing after allogeneic stem cell transplantation.
Montefusco V; Spina F; Patriarca F; Offidani M; Bruno B; Montanari M; Mussetti A; Sperotto A; Scortechini I; Dodero A; Fanin R; Valagussa P; Corradini P
Biol Blood Marrow Transplant; 2013 Mar; 19(3):424-8. PubMed ID: 23142330
[TBL] [Abstract][Full Text] [Related]
16. Treatment of multiple myeloma in the targeted therapy era.
Saad AA; Sharma M; Higa GM
Ann Pharmacother; 2009 Feb; 43(2):329-38. PubMed ID: 19193585
[TBL] [Abstract][Full Text] [Related]
17. The evolving background for high-dose treatment for myeloma.
Sirohi B; Powles R; Harousseau JL; Anderson KC
Bone Marrow Transplant; 2007 Dec; 40(12):1097-100. PubMed ID: 17906702
[TBL] [Abstract][Full Text] [Related]
18. New developments in post-transplant maintenance treatment of multiple myeloma.
Liu H; McCarthy P
Semin Oncol; 2013 Oct; 40(5):602-9. PubMed ID: 24135405
[TBL] [Abstract][Full Text] [Related]
19. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.
Palumbo A; Attal M; Roussel M
Clin Cancer Res; 2011 Mar; 17(6):1253-63. PubMed ID: 21411441
[TBL] [Abstract][Full Text] [Related]
20. Management of newly diagnosed myeloma.
Rajkumar SV; Palumbo A
Hematol Oncol Clin North Am; 2007 Dec; 21(6):1141-56, ix-x. PubMed ID: 17996592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
